The Effect of Gepirone-ER in the Treatment of Sexual Dysfunction in Depressed Men

被引:14
作者
Fabre, Louis F. [1 ]
Clayton, Anita H. [2 ]
Smith, Louis C. [1 ]
Goldstein, Irwin [3 ]
Derogatis, Leonard R. [4 ]
机构
[1] Fabre Kramer Pharmaceut, Houston, TX 77057 USA
[2] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA
[3] Alvarado Hosp, San Diego, CA USA
[4] Sheppard Pratt Hosp, Baltimore, MD USA
关键词
Gepirone-ER; HSDD; Hypoactive Sexual Desire Disorder; 5-HT1A Agonist; DSM-IV Diagnoses of Sexual Disorders; Treatment of Depression and Sexual Dysfunction; FUNCTIONING QUESTIONNAIRE CSFQ; MAJOR DEPRESSION; EXTENDED-RELEASE; DOUBLE-BLIND; DISORDER; EFFICACY; OUTPATIENTS; DESIRE; PREVALENCE; PLACEBO;
D O I
10.1111/j.1743-6109.2011.02624.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Sexual dysfunction is common in patients with major depressive disorder (MDD). Antidepressant medications especially the selective serotonin reuptake inhibitors (SSRIs) may improve depressive symptoms but further decrease sexual function. Gepirone extended release (gepirone-ER) differs from the SSRIs in only affecting the 5-HT1A receptor and has demonstrated efficacy in treatment of depression and sexual dysfunction in depressed women. This report describes the effect of gepirone-ER on sexual function in depressed men. Aim. The aims of this article were to study the effects of gepirone-ER on sexual function in men with MDD and to determine if positive effects are independent of antidepressant or anxiolytic activity. Main Outcome Measures. The main outcome measures of this article were Hamilton depression rating scale (HAMD-17), and changes in sexual functioning questionnaire (CSFQ). Methods. In an 8-week study, gepirone-ER, placebo, or fluoxetine were administered in a double-blind fashion to 181 depressed men. The CSFQ results were used to determine quality of sexual function. To test for an antidepressant or anxiolytic effect, a 50% reduction in HAMD-17 score separated antidepressant responders from nonresponders, and item 12 of the HAMD scale (psychic anxiety) scores of 0 or 1 separated anxiolytic responders from nonresponders. Results. Gepirone-ER treatment improved total sexual function compared with placebo measured by the CSFQ at weeks 4 (P = 0.012) and 8 (P = 0.046). At 4 weeks, almost every CSFQ domain is improved. The orgasm domain was especially improved, 67% by week 4. Gepirone-ER antidepressant and anxiolytic nonresponders showed significant improvement in sexual function. Fluoxetine treatment did not produce improvement. In fact, fluoxetine-treated subjects had lower scores on the total CSFQ, less than placebo, and significantly less than gepirone-ER. Conclusion. Gepirone-ER improves sexual dysfunction in depressed men. All domains of sexual function improved. Gepirone-ER has a pro-sexual effect independent of antidepressant or anxiolytic activity. Fabre LF, Clayton AH, Smith LC, Goldstein I, and Derogatis LR. The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. J Sex Med 2012; 9: 821-829.
引用
收藏
页码:821 / 829
页数:9
相关论文
共 39 条
[1]  
Alpert JE, 2004, J CLIN PSYCHIAT, V65, P1069
[2]  
Amore M, 2009, AGING CLIN EXP RES, V21, P1
[3]   GEPIRONE, A SELECTIVE SEROTONIN (5HT(1A)) PARTIAL AGONIST IN THE TREATMENT OF MAJOR DEPRESSION [J].
AMSTERDAM, JD .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1992, 16 (03) :271-280
[4]  
Baldwin David S, 2004, Expert Opin Drug Saf, V3, P457, DOI 10.1517/14740338.3.5.457
[5]   Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: A double-blind, randomized, placebo-controlled, parallel-group study [J].
Bielski, Robert J. ;
Cunningham, Lynn ;
Horrigan, Joseph P. ;
Londborg, Peter D. ;
Smith, Ward T. ;
Weiss, Kenneth .
JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (04) :571-577
[6]   Serotonin 2A-1438 G/A and G-protein beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects [J].
Bishop, Jeffrey R. ;
Moline, Jessica ;
Ellingrod, Vicki L. ;
Schultz, Susan K. ;
Clayton, Anita H. .
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (10) :2281-2288
[7]   Is there a role for 5-HT1A agonists in the treatment of depression? [J].
Blier, P ;
Ward, NM .
BIOLOGICAL PSYCHIATRY, 2003, 53 (03) :193-203
[8]   The design and conduct of human studies to detect and quantify QT interval prolongation induced by new chemical entities [J].
Camm, AJ .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2002, 16 (02) :141-145
[9]   Prevalence of sexual dysfunction among newer antidepressants [J].
Clayton, AH ;
Pradko, JF ;
Croft, HA ;
Montano, CB ;
Leadbetter, RA ;
Bolden-Watson, C ;
Bass, KI ;
Donahue, RMJ ;
Jamerson, BD ;
Metz, A .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (04) :357-366
[10]  
Clayton AH, 1997, PSYCHOPHARMACOL BULL, V33, P731